Sir,
We read the article "Rhino-orbito-cerebral mucormycosis in a child with diabetic ketoacidosis (DKA)" by Kumar et al. [1] with interest. The author reported a 9-year-old girl with DKA and rhino-orbito-cerebral mucormycosis. We want to highlight certain issues regarding diagnosis and management of this child.
The child was diagnosed with rhino-orbital-cerebral mucormycosis after 48 h of admission. Her initial computed tomography (CT) brain was found to be normal. It is not clear whether the CT brain was plain or contrast enhanced. We can understand due to sickness of the child, CT may have been preferred over magnetic resonance imaging (MRI). However in a clinical scenario where cerebral invasion is suspected along with rhinosinusitis, MRI is preferred over CT scan. Contrast enhanced T1-weighed images are helpful in delineating intracranial spread and identifying invasion of cavernous portion of internal carotid artery. [2, 3] The sensitivity of initial CT and MRI in detecting sinusitis is 97% and 100% respectively. However, initial MRI is more sensitive in detecting disease beyond sinuses like extension to orbits, cranium. [4] Since, she developed ophthalmoplegia at 72 h of admission, cavernous sinus thrombosis should be strongly suspected. Involvement of brain stem could not be ruled out as she had right facial palsy with left hemiparesis.
Authors have mentioned amphotericin B as the treatment of choice in mucormycosis, but the current literature suggests that combination antifungal therapy is better than monotherapy in mucormycosis. Reed et al. concluded from a retrospective study that combination of caspofungin-polyene therapy is superior to polyene monotherapy. [4] Addition of echinocandins to polyenes increases the efficiency of polyenes by following mechanisms:  Disruption of  glucan linking on the cell wall of Rhizopus resulting in better delivery of polyenes  Altered virulence of fungus by stunting fi lamentation or altering cell wall contents  Enhanced host response to the fungus. 
Nosocomial candiduria in chronic liver disease patients at a hepatobilliary center
Sir, We read the article "Nosocomial candiduria in chronic liver disease patients at a hepatobiliary center" [1] with great interest. This article clearly highlights the importance of repeat sampling in patients who are reported as having candiduria. Candiduria can occur due to contamination, colonization (of the indwelling catheter or bladder), and infection (Candida cystitis or ascending pyelonephritis or renal candidiasis) as discussed in this article. Taking a repeat sample after insertion of fresh catheter eliminates the chances of contamination, but colonization can still be present without any clinical manifestation of disease. [2, 3] 
Differentiation between the colonization and infection is diffi cult one and should be interpreted in the light of clinical features. Frequently, due to the presence of multiple co morbidities the line of demarcation between
Candida colonization and infection is blurred, more so in critically ill patients.
Pathogenesis of urinary tract and renal infections caused by
Candida involves hematogenous spread as well ascending infection. When suspecting hematogenous spread various risk prediction scores (colonization index, Candida score) have been designed to guide therapy. [3, 4] Candida colonization has been shown to be a risk factor for invasive candidiasis, but multiple site colonization and heavy colonization is considered more signifi cant than single site colonization. [5] Candiduria represents single site colonization and should not trigger initiation of treatment unless other symptoms are also present. When suspecting ascending infection, one should look for predisposing factors like presence of stone or presence of obstruction, urinary drainage devices, prior surgical procedures, broad spectrum antibiotic use, old age, and diabetes mellitus.
Infectious Disease Society of America 2009 guidelines recommends that asymptomatic candiduria should not be treated unless the patient is at high risk of invasive candidiasis (neutropenia, low birth weight, and patients who undergo urologic procedures). [6] The reason for treating asymptomatic candiduria in high risk patients is mainly prophylaxis.
Chronic liver disease is a very broad terminology and includes various etiologies and stages of evolution in its natural history. Whether all chronic liver disease patients should be included in the high risk remains to be established. Currently, there is a paucity of literature regarding predisposition for invasive Candida infections among chronic liver disease patients. It would have been enlightening if the patient characteristics and stages/classifi cation of liver disease were also mentioned in this study.
The study also reports that 11 (3.5%) patients of candiduria evolved to candidemia. Though it is diffi cult to perform, genotypic identifi cation is ideally required before one can say that species colonizing is the same as the species responsible for blood stream infection.
